(Q37131239)

18 August 2017

1 reference

title

Protection against Parkinson's disease progression: clinical experience (English)

1 reference

18 August 2017

1 reference

Peter A LeWitt

1

1 reference

18 August 2017

Danette C Taylor

series ordinal

2

1 reference

18 August 2017

1 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

5

1 reference

18 August 2017

2

1 reference

18 August 2017

210-225

1 reference

Treatment of Parkinson's disease with trophic factors

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Assessment of the progression of Parkinson's disease: a metabolic network approach

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Changes in network activity with the progression of Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

How to judge animal models of Parkinson's disease in terms of neuroprotection.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

A responsive outcome for Parkinson's disease neuroprotection futility studies

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

The role of radiotracer imaging in Parkinson disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Levodopa and the progression of Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Levodopa in the treatment of Parkinson's disease: current controversies

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Molecular Pathways of Neurodegeneration in Parkinson's Disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Neuroprotective strategies in Parkinson's disease : an update on progress

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Oxidative stress in Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Do dopamine agonists or levodopa modify Parkinson's disease progression?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Are dopamine receptor agonists neuroprotective in Parkinson's disease?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Excitatory amino acids as a final common pathway for neurologic disorders.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Ageing and Parkinson's disease: substantia nigra regional selectivity

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Neuroprotection in Parkinson models varies with toxin administration protocol

27 June 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Freezing of gait in PD: prospective assessment in the DATATOP cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

The effect of deprenyl washout in patients with long-standing Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Neuroprotective effects of pramipexole in young and aged MPTP-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

l-DOPA administration enhances 6-hydroxydopamine generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Creatine and cyclocreatine attenuate MPTP neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Selective vulnerability of dopaminergic neurons to microtubule depolymerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084164

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan

3 September 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.007

Gene therapy for Parkinson's disease

21 January 2018

1 reference

12 December 2020

Selegiline slows the progression of the symptoms of Parkinson disease

1 reference

12 December 2020

DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway

1 reference

12 December 2020

A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

Study design problems of DATATOP study analysis

1 reference

12 December 2020

The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.

1 reference

12 December 2020

The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study

1 reference

12 December 2020

L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion

1 reference

12 December 2020

Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole

1 reference

12 December 2020

Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer

1 reference

12 December 2020

1 reference

12 December 2020

Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine

1 reference

12 December 2020

Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice

1 reference

12 December 2020

Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation

1 reference

12 December 2020

Selegiline as a primary treatment of Parkinson's disease

1 reference

12 December 2020

An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture.

1 reference

12 December 2020

Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

1 reference

12 December 2020

A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone)

1 reference

12 December 2020

Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole

1 reference

12 December 2020

A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group

1 reference

12 December 2020

The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD

1 reference

12 December 2020

Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide

1 reference

12 December 2020

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

12 December 2020

10.1016/J.NURT.2008.01.007

Identifiers

DOI

1 reference

Dimensions Publication ID

18 August 2017

0 references

1 reference

18 August 2017

PubMed publication ID

18394564

1 reference